PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN.\', \'Hematopoietic Cellular Therapy Program, Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL.\', \'Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York, NY.\', \'Division of Hematology Oncology, Department of Medicine, Vanderbilt School of Medicine, Nashville, TN.\', \'Section of Cellular Therapy and Transplant, Children\'s Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.\', \'Knight Cancer Institute, Oregon Health & Science University, Portland, OR.\', \'Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS.\', \'Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.\', \'University of Pennsylvania and Abramson Cancer Center, Philadelphia, PA. Electronic address: david.porter@pennmedicine.upenn.edu.\', \'Hematopoietic Cellular Therapy Program, Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL. Electronic address: priedell@medicine.bsd.uchicago.edu.\']
?:citedBy
  • -1
?:creator
?:doi
  • S1083-8791(20)30217-210.1016/j.bbmt.2020.04.008
?:doi
?:hasPublicationType
?:journal
  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
is ?:pmid of
?:pmid
?:pmid
  • 32298807
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
?:title
  • Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic.
?:type
?:year
  • 2020

Metadata

Anon_0  
expand all